Journal of Biomedical Engineering

A Critical Analysis of Polymersome Therapeutics: From Laboratory to Large-Scale Production

Beatriz Nogueira Messias de Miranda^1,2, Wesley Luzetti Fotoran³, Gerhard Wunderlich³, Emanuel Carrilho^2,4 and Adriano Marim de Oliveira¹*

¹Instituto de Pesquisas Tecnológicas do Estado de Sao Paulo (IPT), Bionanomanufacturing Center, Brazil

²Instituto de Química de Sao Carlos, Universidade de Sao Paulo, Brazil

³Instituto de Ciencias Biomédicas, Universidade de Sao Paulo, Brazil

⁴Instituto Nacional de Ciencia e Tecnologia de Bioanalítica-INCTBio, Brazil

Submission: March 03, 2018; Published: May 21, 2018

*Corresponding author: Adriano Marim de Oliveira, Instituto de Pesquisas Tecnológicas do Estado de Sao Paulo (IPT), Bionanomanufacturing Center, Sao Paulo-SP, Brazil, Email: miranda@ipt.br

How to cite this article: Beatriz Nogueira Messias de Miranda, Wesley Luzetti Fotoran, Gerhard Wunderlich, Emanuel Carrilho, Adriano Marim de Oliveira. A Critical Analysis of Polymersome Therapeutics: From Laboratory to Large-Scale Production. Curr Trends Biomedical Eng & Biosci. 2018; 14(4): 555892. DOI: 10.19080/CTBEB.2018.14.555892

Introduction

Polymersomes as a synthetic evolution of liposomes

Vesicular compartments are responsible for an organized separation within the cell and were crucial to the generation of life and the evolution. Vesicles produced by self-assembling of amphiphilic lipids arose as a promising technology for mimicking bio-available compartments, as well as its advantages related to chemical gradients, energy storage, stimuli responsiveness, and others. After the first description of liposomes in the mid-60s, they became present in many biotechnological applications. In 2005, the FDA approved the first liposome-based drug delivery carrier, Doxil® (doxorubicin HCl liposome injection, Janssen Products, LP). Over the years, the use of an inert polymer as an adjuvant in liposome constitution was vital, and polyethylene glycol (PEG) provided improvements in biodistribution with minimal side effects [1], both of which relevant characteristics for drug delivery [2,3]. Therefore, polymersomes, comprised of amphiphilic block copolymers (BCPs), emerged as a promising alternative to liposomes [4,5]. Both present analog lamellar membrane structure. Polymer vesicles display modifications in structural features of self-assembled vesicles, and therefore show enhanced stability compared with liposomes. Moreover, the high diversity and versatility of synthetic polymers enables the modulation of physicochemical properties related to membrane thickness, composition, permeability, stimuli- responsiveness, particle morphology and size, according to the desired application [6-12]. He high stability and robustness of these structures, however, could be addressed as a disadvantage towards becoming a functional drug delivery system. For this reason, stimuli-responsive polymersomes appear as an alternative to deliver the inside content upon demand, using, for instance pH, temperature, and osmotic differences, or ultrasound as an exogenous stimulus [13,14]. Moreover, biocompatible polymersomes were already tested in vivo as drug carriers and demonstrated its great potential for therapeutic applications [15,16].

Loading polymersomes with cargos and its structural consequences

Regarding drug delivery, the existence of an aqueous core - like liposomes - enables loading of hydrophilic drugs while hydrophobic drugs can be included within their amphiphilic membranes [6-11,17]. While the concomitant use of different active principles may seem an interesting strategy for disease treatment, the interaction between the external molecule and the block copolymer branches may interfere in the morphology of the particle, which is illustrated in Figure 1. Such interference may be one of the drawbacks regarding self-assembly vesicle formation with the drug acting similarly to a blend of substances producing a worm-like micelle morphology [15].

The self-assembling or self-organization process depends on the interfacial energy related to the hydrophilic/hydrophobic interface, that tends to compensate the loss of entropy due to the polymer linkage [12]. Unfortunately, polymersomes production is not trivial. Key experimental conditions such as the nature of the solvent, type and concentration of the polymer, water disponibility, temperature and external shear forces, in addition to macromolecular parameters appear to have great influence on the self-assembling process, affecting e.g., aggregate morphology and size [1]. Predictions of aggregate morphologies were proposed based mainly on macromolecular parameters such as hydrophilic and hydrophobic balance (hydrophilic weight fraction /, for PEG hydrophobic parts), in which the increase of / seems to favor spherical or worm-like micelles, while the decrease produces hollow structures, including vesicles [15]. Nevertheless, such a prediction cannot be considered as universal, and the effective outcome depends strongly on the polymer chain structure and characteristics [1]. Moreover, even though BCPs can also self-assemble into vesicles when hydrated, commonly used preparation methods for polymersomes rely on (i) film hydratation approaches--what is somewhat inefficient or very time consuming requiring up to one month if used solely--, or (ii) bulk methods, such as the solvent-switching and double emulsion approaches--which require the use of organic solvents, often not suitable for biomedical application [9,18].

Further, the size plays an important role, especially for intravenous injection, permeability, and retention (EPR effect). For that reason, techniques well established for liposomes that improve homogeneity and size (post-formation resizing) including extrusion through polycarbonate filters, freeze- thaw cycles and/or, sonication are applied for the same intent [2,19,20]. Since the use of membrane extrusion is timeconsuming, expensive, and risky (clogging of the system is a frequent phenomenon), it is limited to the laboratory scale. This may be achieved by the use of other techniques such as sonication or freezing, but still, rely on high energy input requirements.

Clearly, a major drawback of this technology is the preparation step, which is time-consuming and difficult for high- throughput setups. This may be the reason why there are still no commercially available products based on polymer vesicles.

New methods for scaling-up the production of polymersomes

A first report discussing the value of developing industry- scale polymersome production techniques was by published Poschenrieder et al. [21] who described a fundamental study regarding polymersome production via the ethanol method in a stirred-tank reactor [21,22]. Even though it was an important contribution to the field, such an approach may not be universally used as it still depends on the BCP's characteristics. Novel microfluidic methods for polymersome preparation techniques have emerged and since then, efforts have been concentrated mainly in device parallelization for industrial applications [23]. Devices such as a tandem emulsification device provide a promising alternative.

The fact that novel protocols for scaling-up are emerging indicates that the field is moving forward. One has to keep in mind that it took almost four decades until the approval of the first FDA-approved liposomal-based drug formulation and polymersomes exist only for two decades. In order to move closer to commercialization, significant developments are necessary in the process of self-assembly either for bulk production or for microfluidic production in industrial scale. Breakthroughs in this direction are expected.

Acknowledgement

This work was funded in part by CNPq (207254/2014-1), by the Institute for Technological Research, IPT, and the Institute for Technological Research Foundation, FIPT, for infrastructure and a fellowship for B.N.M.M. The National Institute for Science and Technology in Bioanalytics - INCTBio kindly acknowledges FAPESP (grant # 2014/50867-3) and CNPq (grant # 465389/2014-7) for their support.